, June 4, 2014
/PRNewswire/ - Norgen Biotek Corp., an innovative
privately held Canadian biotechnology company focusing primarily on
advancing powerful tools for nucleic acids (NA) and protein
purification, today announced the launch of 6 novel kits for the fast
and simple isolation of NA from blood, plasma/serum and urine,
including cell-free-circulating (cfc)RNA, cfcDNA and sequential cfcDNA
and cfcRNA. Data from comparisons of these kits with similar kits on
the market clearly indicates that NBC's kits yield significantly more
diverse cfcRNA, owing to the fact that NBC kits use a proprietary resin
technology that has the ability to bind all RNA sequences irrespective
of size or GC content. Moreover, these new kits are both rapid and
robust. The sensitivity and speed of these novel kits make them very
powerful tools for a number of applications including the sensitive
detection of tumor biomarkers and viruses, microRNA detection by PCR,
quantitative PCR, RT-PCR, microarrays, Next Gen Sequencing, etc.
NBC's blood/plasma/serum and urine kits utilize a convenient spin column
format for NA purification, and both fresh and frozen samples can be
processed. In particular, the circulating NA kits provide a major
advantage over other available kits in that they isolate significantly
more diverse cfcRNA than any other technology on the market.
Circulating NA present in 200 mL plasma inputs (or 3.0 mL of urine
inputs) are concentrated into final elution volumes of 10 mL that can
be used directly in sensitive downstream applications, as the kits
completely remove all contaminants and inhibitors. Novel Kits with
similar specifications to process up to 5 mL of plasma/serum (and up to
50ml of urine) specimens will be launched during the next couple of
"We are confident that this basket of new kits represents a very
exciting addition to our line of high quality products. These kits
capture significantly more diverse cfcRNA (microRNA) from a given
specimen than any other kit on the market, and therefore these kits are
a must for scientists who diligently screened (or currently screening)
plasma yet are missing a significant number of targets or useful
biomarkers. Re-examination of these specimens with our novel kits
would allow these scientists to detect all those microRNAs that were
missed in the previous screenings. We also offer contract R&D to
re-isolate cfcRNA and cfcDNA from these same specimens. Our mission is
to accelerate discovery by bringing to market innovative Best-in-Class
sample preparation products that can be used in research as well as in
MDx applications." said Dr. Haj-Ahmad, President & CEO of NBC.
About Norgen Biotek Corp.
NBC, an ISO 15189:2007, ISO 13485:2003 and ISO 9001:2008 registered
company, is a privately-held Canadian biotech company committed to
providing innovative products and services to the life sciences and
pharmaceutical industry. NBC is applying its proprietary technologies
to develop best-in-class products for the purification of NA and
proteins as well as Mdx. Currently, NBC is focused on developing
diagnostics for resources limited areas, point-of-care and home use.
Detailed information about the company is available at www.norgenbiotek.com or contact Dr. Yousef Haj-Ahmad, President & CEO, NBC Phone: (905)
227-8848, Fax: (905) 227-1061, Email: firstname.lastname@example.org.
SOURCE Norgen Biotek Corp.